A2BAR Antagonism Mitigates Pulmonary Inflammation and Fibrosis and Restores Macrophage M1/M2 Balance in Diabetic Rats
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188171 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ángelo Torres-Arévalo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Escuela de Medicina Veterinaria, Facultad de Recursos Naturales y Medicina Veterinaria, Sede Talca, Universidad Santo Tomás, Talca 347-3620, Chile. Hauptthemen laut MEDLINE: Pneumonia, Macrophages, Diabetes Mellitus, Experimental, Pulmonary Fibrosis. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico, Agencia Nacional de Investigación y Desarrollo de Chile.
Abstract (Originalsprache)
The pathophysiological mechanisms underlying diabetic lung disease (DLD) remain poorly understood. Beyond hyperglycemia, dysregulated molecules such as adenosine may contribute to pulmonary inflammation and fibrosis. MRS1754, a selective antagonist of the A2B adenosine receptor (A2BAR), has demonstrated anti-inflammatory and antifibrotic effects, including reductions in macrophage (MΦ) infiltration in animal models of diabetes-associated complications; however, its effects on DLD remain unexplored. Here, diabetic Sprague-Dawley rats were treated with MRS1754, and pulmonary inflammation, fibrosis, MΦ infiltration, and polarization were assessed in bronchoalveolar lavage fluid (BALF) and lung tissue using immunohistopathological and molecular approaches. According to data normality, one-way ANOVA/Tukey’s test or Kruskal–Wallis/Dunn’s test were employed, as appropriate; ordinal data were analyzed using the Mann–Whitney test with Bonferroni correction. Compared with controls, diabetic rats exhibited pulmonary inflammation and fibrosis, increased MΦ infiltration, and an M1/M2 polarization imbalance. MRS1754 attenuated these alterations, reducing Tumor necrosis factor-alpha (TNF-α) and Transforming growth factor-beta 1 (TGF-β1) levels, decreasing MΦ accumulation in BALF and lung tissue, and fully restoring the M1/M2 balance to control levels. BALF MΦ populations, particularly the M2 (Cluster of differentiation 163-positive; CD163+) subset, correlated strongly with TGF-β1 and fibronectin (FN1) levels. Reanalysis of human fibrotic lung single-cell transcriptomic data further identified MΦ as a major TGF-β1-expressing cell population. Collectively, these findings suggest that A2BAR antagonism partially mitigates inflammation, fibrosis, and MΦ infiltration while fully restoring MΦ polarization balance in DLD, supporting its potential as a therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Escuela de Medicina Veterinaria, Facultad de Recursos Naturales y Medicina Veterinaria, Sede Talca, Universidad Santo Tomás, Talca 347-3620, Chile.
- Facultad de Salud, Institución Universitaria Colegio Mayor de Antioquia, Medellín 050036, Colombia.
- Laboratorio de Inmunoepigenética, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia 511-0566, Chile.
- Laboratorio de Patología Molecular, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia 511-0566, Chile.
- Tumor Biology Laboratory, Institute of Biochemistry and Microbiology, Faculty of Sciences, Universidad Austral de Chile, Valdivia 511-0566, Chile.
- Millennium Institute on Immunology and Immunotherapy, Universidad Austral de Chile, Valdivia 511-0566, Chile.
ORCID-Profile: Ángelo Torres-Arévalo, Sebastián Alarcón, Benjamín Guerrero, Pamela Silva, Víctor Pola-Véliz
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico
- Agencia Nacional de Investigación y Desarrollo de Chile
Zitieren
APA
Torres-Arévalo, Á., Montoya-Muñoz, S., Montes-Vanegas, M., Cappelli-León, C., Árias, I., Cancino, C. J., Quezada, C., Alarcón, S., Guerrero, B., Silva, P., Pola-Véliz, V., & San Martín, R. (2026). A2BAR Antagonism Mitigates Pulmonary Inflammation and Fibrosis and Restores Macrophage M1/M2 Balance in Diabetic Rats. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188171
Vancouver
Torres-Arévalo Á, Montoya-Muñoz S, Montes-Vanegas M, Cappelli-León C, Árias I, Cancino CJ, et al. A2BAR Antagonism Mitigates Pulmonary Inflammation and Fibrosis and Restores Macrophage M1/M2 Balance in Diabetic Rats. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188171
BibTeX
@article{TorresArvalo2026,
author = {Torres-Arévalo, Ángelo and Montoya-Muñoz, Sarah and Montes-Vanegas, Mateo and Cappelli-León, Claudio and Árias, Ignacio and Cancino, Claudia Jara and Quezada, Claudia and Alarcón, Sebastián and Guerrero, Benjamín and Silva, Pamela and Pola-Véliz, Víctor and San Martín, Rody},
title = {A2BAR Antagonism Mitigates Pulmonary Inflammation and Fibrosis and Restores Macrophage M1/M2 Balance in Diabetic Rats},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188171}
}
EUVIMED